|
NLG919
- 英文名称：NLG919
- 品牌：WYTSCI
- 产地：进口
- 型号：1MG
- 货号：WT-AY-B11285
- cas：1402836-58-1
- 价格： ￥1/mg
- 发布日期： 2025-04-10
- 更新日期： 2025-05-23
产品详请
| 产地 | 进口 |
| 品牌 | WYTSCI |
| 货号 | WT-AY-B11285 |
| 用途 | 科研检测 |
| 英文名称 | NLG919 |
| 包装规格 | 1MG |
| CAS编号 | 1402836-58-1 |
| 别名 | NLG919 |
| 纯度 | 98+% |
| 分子式 | |
| 是否进口 | 是 |
纯度:985 by TLC,;NMR (Conforms)
分子式:C18H22N2O
分子量:282.39
溶剂:DMSO (10 mg/ml)
性状:White solid
存储:-20°C
Activity (short version):IDO pathway inhibitor
Function / Pharmacology:NLG919 (1402836-58-1) is a potent IDO-pathway inhibitor (Ki = 7nM; EC50 = 75nM).1 It synergizes with chemo-radiation therapy to promote T cell dependent complement deposition in a murine model of glioblastoma.2 In combination with paclitaxel in a mouse B16-F10 melanoma model, NLG919 increased the percentage of CD3+, CD8+, and CD4+ T cells and secretion of IFN-γ and interleukin-2 while decreasing the percentage of CD4+CD25+ regulatory T cells.3
分子式:C18H22N2O
分子量:282.39
溶剂:DMSO (10 mg/ml)
性状:White solid
存储:-20°C
Activity (short version):IDO pathway inhibitor
Function / Pharmacology:NLG919 (1402836-58-1) is a potent IDO-pathway inhibitor (Ki = 7nM; EC50 = 75nM).1 It synergizes with chemo-radiation therapy to promote T cell dependent complement deposition in a murine model of glioblastoma.2 In combination with paclitaxel in a mouse B16-F10 melanoma model, NLG919 increased the percentage of CD3+, CD8+, and CD4+ T cells and secretion of IFN-γ and interleukin-2 while decreasing the percentage of CD4+CD25+ regulatory T cells.3
